Public policy and patient advocacy
We engage with governments, policymakers, multilateral agencies, and professional associations to advocate for policies that protect the interests of patients, while supporting our business. We also engage with and support patient groups togain insights from patients, to help us develop products and advocate for policies that better meet their needs.
We aim to demonstrate that all our interactions with political stakeholders and patient advocacy groups are conducted appropriately, ethically and transparently. We publish our criteria for working with public policy groups to give clarity on our approach.
Medicines and vaccines bring significant benefits for individual patients and for public health. In order to realise these benefits we need to interact with external groups throughout the research, development and marketing of our medicines and vaccines. This enables us to use the expertise of patients, scientists, doctors and other healthcare professionals to better understand how to conduct the most effective research, how to make treatment advances and how to meet patient needs.
In some instances these interactions involve GSK providing funding to an organisation or an individual. We know these relationships can cause concern and we therefore aim to be transparent about the payments we make and what they are for.
Patient group funding
We provide funding to patient groups to help with day-to-day running costs and defined events or activities. Our support also includes educational assistance, training for staff, and collaboration on disease awareness and prevention projects. Our relationships with patient groups help us to better understand patient needs and their illnesses, which guides our R&D. In turn, our support helps patient opinions to be heard in the healthcare debate.
Grants and funding from GSK cannot exceed 25% of patient groups’ annual revenue and we do not exert undue influence or promote our products to these organisations.
Find details of our work with patient groups in our US, Europe, Asia Pacific, and Emerging Markets regions, as well as what funding we provide for patient groups working globally.
Our community investment aims to improve health education and increase access to medicines and healthcare services. We target support where we can make the most difference.
We are transparent about our charitable giving and report global figures in our Annual Report and Responsible Business Supplement. You can download information about our annual grants over £10,000 ($20,000) on our Charitable grants page.